Low-dose 90Y PET/CT imaging optimized for lesion detectability and quantitative accuracy: a phantom study to assess the feasibility of pretherapy imaging to plan the therapeutic dose.

Nucl Med Commun

aDepartment of Medical Radiation Engineering, Shahid Beheshti University bResearch Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran cDepartment of Radiology dDepartment of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, Maryland, USA.

Published: November 2017

Objective: The overall aim of this work is to optimize the reconstruction parameters for low-dose yttrium-90 (Y) PET/CT imaging, and to determine Y minimum detectable activity, in an endeavor to investigate the feasibility of performing low-dose Y imaging in-vivo to plan the therapeutic dose in radioembolization.

Materials And Methods: This study was carried out using a Siemens Biograph 6 True Point PET/CT scanner. A Jaszczak phantom containing five hot syringes was imaged serially over 15 days. For 128 reconstruction parameters/algorithms, detectability performance and quantitative accuracy were evaluated using the contrast-to-noise ratio and the recovery coefficient, respectively.

Results: For activity concentrations greater than 2.5 MBq/ml, the linearity of the scanner was confirmed while the corresponding relative error was below 10%. Reconstructions with smaller numbers of iterations and smoother filters led to higher detectability performance, irrespective of the activity concentration and lesion size. In this study, the minimum detectable activity was found to be 3.28±10% MBq/ml using the optimized reconstruction parameters. Although the recovered activities were generally underestimated, for lesions with activity concentration greater than 4 MBq/ml, the amount of underestimation is limited to -15% for optimized reconstructions.

Conclusion: Y PET/CT imaging, even with a low activity concentration, is feasible for depicting the distribution of Y implanted microspheres using optimized reconstruction parameters. As such, in-vivo PET/CT imaging of low-dose Y in the pretherapeutic stage may be feasible and fruitful to optimally plan the therapeutic activity delivered to patients undergoing radioembolization.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000742DOI Listing

Publication Analysis

Top Keywords

pet/ct imaging
16
plan therapeutic
12
reconstruction parameters
12
activity concentration
12
quantitative accuracy
8
therapeutic dose
8
minimum detectable
8
detectable activity
8
detectability performance
8
optimized reconstruction
8

Similar Publications

Purpose: The study explores the role of multimodal imaging techniques, such as [F]F-PSMA-1007 PET/CT and multiparametric MRI (mpMRI), in predicting the ISUP (International Society of Urological Pathology) grading of prostate cancer. The goal is to enhance diagnostic accuracy and improve clinical decision-making by integrating these advanced imaging modalities with clinical variables. In particular, the study investigates the application of few-shot learning to address the challenge of limited data in prostate cancer imaging, which is often a common issue in medical research.

View Article and Find Full Text PDF

Clinical significance of post-chemoradiotherapy 2-[F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.

Oral Oncol

February 2025

Department of Nuclear Medicine, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China. Electronic address:

Purpose: To investigate the prognostic value of post-chemoradiotherapy 2-[F]FDG PET/CT in locally advanced nasopharyngeal carcinoma (LANPC) and develop an accurate prognostic model based on the 2-[F]FDG PET/CT results.

Methods: 900 LANPC patients who underwent pretreatment and post-chemoradiotherapy 2-[F]FDG PET/CT from May 2014 to August 2022 were included in the study. We divided the patients into two distinct cohorts for the purpose of our study: a training cohort comprising 506 individuals, included from May 2008 to April 2020, and a validation cohort consisting of 394 individuals, included from May 2020 to August 2022.

View Article and Find Full Text PDF

Purpose: Receptor CUB-domain containing- protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer.

Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423 patients (119 triple-negative breast cancer (TNBC); 75 HER2+; 229 ER+/HER2- including 228 primary tumors, 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER2-targeting ADC T-DM1.

View Article and Find Full Text PDF

Introduction: The generalizability of neuroimaging and cognitive biomarkers in their sensitivity to detect preclinical Alzheimer's disease (AD) and power to predict progression in large, multisite cohorts remains unclear.

Method: Longitudinal demographics, T1-weighted magnetic resonance imaging (MRI), and cognitive scores of 3036 cognitively unimpaired (CU) older adults (amyloid beta [Aβ]-negative/positive [A-/A+]: 1270/1558) were included. Cross-sectional and longitudinal cognition and medial temporal lobe (MTL) structural measures were extracted.

View Article and Find Full Text PDF

Background: Penile metastasis originating from prostate cancer is an extremely rare condition, typically associated with a poor prognosis. Therapeutic approaches are not well established and may require individualized adaptation based on clinical assessment. Radiotherapy is commonly utilized to alleviate symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!